Research programme: anticancer therapeutics - Hercules Pharmaceuticals

Drug Profile

Research programme: anticancer therapeutics - Hercules Pharmaceuticals

Alternative Names: CB 7993113

Latest Information Update: 06 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hercules Pharmaceuticals
  • Class
  • Mechanism of Action Aryl hydrocarbon receptor antagonists; Cytochrome P-450 enzyme system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 02 Nov 2015 Pharmacodynamics data from a preclinical study in cancer models released by Hercules Pharmaceuticals
  • 02 Nov 2015 Preclinical trials in Breast cancer in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top